Autoantibodies against the catalytic domain of BRAF are not specific serum markers for rheumatoid arthritis

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Li, Wenli ^a,b   Wang, Wei ^a,b   Sun, Shipeng ^a,b   Sun, Yu ^a,b   Pan, Yang ^a,b   Wang, Lunan ^a   Zhang, Rui ^a   Zhang, Kuo ^a   Li, Jinming ^a  

^a BEIJING HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AUTOANTIBODY; B RAF KINASE; B RAF KINASE ANTIBODY; P25 ANTIBODY; PEPTIDE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PEPTIDE SYNTHESIS; PROTEIN DOMAIN; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIBODY PRODUCTION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; DEMOGRAPHY; ENZYME ACTIVE SITE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CASE-CONTROL STUDIES; CATALYTIC DOMAIN; DEMOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; RECOMBINANT PROTEINS;

EID: 83155176341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028975     Document Type: Article

References (22)

1. Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT, (2007) Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Crit Rev Clin Lab Sci 44: 339-363.
2. Auger I, Balandraud N, Rak J, Lambert N, Martin M, et al. (2009) New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 68: 591-594.
3. Schaeffer HJ, Weber MJ, (1999) Mitogen-activated protein kinase: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
5. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, et al. (2002) Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40: 580-581.
6. Luo SF, Fang RY, Hsieh HL, Chi PL, Lin CC, et al. (2010) Involvement of MAPKs and NF-kappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule 1 expression in human rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 62: 105-116.
7. Schett G, Zwerina J, Firestein G, (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67: 909-916.
8. Thalhamer T, McGrath MA, Harnett MM, (2008) MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 47: 409-414.
9. Sweeney SE, Firestein GS, (2004) Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 16: 231-237.
10. Charpin C, Martin M, Balandraud N, Roudier J, Auger I, (2010) Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Res Ther 12: R194.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
12. Wang W, Li J, (2011) Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis. Clin Rheumatol 30: 563-567.
13. Yang JC, Blanton RE, King CL, Fujioka H, Aikawa M, et al. (1996) Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein. Infect Immun 64: 3584-3591.
14. Di Bonito P, Grasso F, Mochi S, Accardi L, Donà MG, et al. (2006) Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer 1: 6-14.
15. Richards HB, Satoh M, Shaw M, Libert C, Poli V, et al. (1998) Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 188: 985-990.
16. Chang L, Karin M, (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
17. Tak PP, Firestein GS, (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
18. Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, et al. (1998) Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 273: 24832-24838.
19. Lacki JK, Samborski W, Mackiewicz SH, (1997) Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16: 275-278.
20. Westermarck J, Li SP, Kallunki T, Han J, Kähäri VM, (2001) p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Mol Cell Biol 21: 2373-2383.
21. Fensterle J, Becker JC, Potapenko T, Heimbach V, Vetter CS, et al. (2004) B-Raf specific antibody responses in melanoma patients. BMC Cancer 4: 62-70.
22. Johansson AG, Løvdal T, Magnusson KE, Berg T, Skogh T, (1996) Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 24: 169-175.